Larimar Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Larimar Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 3.5% beneficial ownership stake in Larimar Therapeutics, Inc.
NASDAQ
Blue Owl Capital Holdings LP has increased its beneficial ownership in Larimar Therapeutics, Inc. to 9.99% of common stock.
NASDAQ
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a shared beneficial ownership of 5.8% of Larimar Therapeutics, Inc. common stock.
NASDAQ
Opaleye Management, L.P., and James Silverman have disclosed a 4.80% beneficial ownership stake in Larimar Therapeutics, Inc. common stock.
NASDAQ
Janus Henderson Group plc has reported a 0.0% beneficial ownership in Larimar Therapeutics, Inc., indicating a full divestment of its previous holdings.
NASDAQ
Millennium Management LLC, along with its affiliates and founder Israel A. Englander, has disclosed a beneficial ownership of 5.6% in Larimar Therapeutics, Inc., totaling 3,563,602 shares of common stock.
NASDAQ
Janus Henderson Group PLC and its subsidiary, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed beneficial ownership stakes in Larimar Therapeutics, Inc., as detailed in a recent Schedule 13G filing.
NASDAQ
SCHEDULE 13G/A: Goldman Sachs Reduces Stake in Larimar Therapeutics to 4.1%
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a beneficial ownership of 4.1% in Larimar Therapeutics, Inc. common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 4.8% Passive Stake in Larimar Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% of Larimar Therapeutics, Inc.'s common stock as of March 31, 2025.
NASDAQ
Opaleye Management, Inc., along with Opaleye, L.P. and James Silverman, has reported a 6.17% beneficial ownership stake in Larimar Therapeutics, Inc. common stock.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, revealing a passive beneficial ownership of 5.1% in Larimar Therapeutics, Inc. as of December 31, 2024.
NASDAQ
Janus Henderson Group PLC and its affiliated entities have reported a combined beneficial ownership of 10.1% in Larimar Therapeutics, Inc. as of December 31, 2024.